MX2016006292A - Formulacion compuesta que comprende tadalafilo y amlodipina. - Google Patents
Formulacion compuesta que comprende tadalafilo y amlodipina.Info
- Publication number
- MX2016006292A MX2016006292A MX2016006292A MX2016006292A MX2016006292A MX 2016006292 A MX2016006292 A MX 2016006292A MX 2016006292 A MX2016006292 A MX 2016006292A MX 2016006292 A MX2016006292 A MX 2016006292A MX 2016006292 A MX2016006292 A MX 2016006292A
- Authority
- MX
- Mexico
- Prior art keywords
- tadalafil
- amlodipine
- composite formulation
- parts
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Inorganic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se proporciona una formulación compuesta que incluye: tadalafilo o una sal farmacéuticamente aceptable del mismo como ingrediente activo; y amlodipina o una sal farmacéuticamente aceptable de la misma como ingrediente activo, en la que una cantidad total de tadalafilo y amlodipina está en un intervalo de alrededor de 6 partes a alrededor de 16 partes en peso basado en 100 partes en peso de un peso total de la formulación compuesta.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130139334 | 2013-11-15 | ||
KR1020140096022A KR20150056443A (ko) | 2013-11-15 | 2014-07-28 | 타다라필 및 암로디핀을 포함하는 복합제제 |
PCT/KR2014/010641 WO2015072700A1 (en) | 2013-11-15 | 2014-11-06 | Composite formulation comprising tadalafil and amlodipine |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016006292A true MX2016006292A (es) | 2016-09-08 |
Family
ID=53391753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016006292A MX2016006292A (es) | 2013-11-15 | 2014-11-06 | Formulacion compuesta que comprende tadalafilo y amlodipina. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20160263040A1 (es) |
EP (1) | EP3068380A4 (es) |
JP (1) | JP2016539934A (es) |
KR (3) | KR20150056443A (es) |
CN (1) | CN105744930A (es) |
AR (1) | AR098415A1 (es) |
AU (1) | AU2014349417A1 (es) |
CA (1) | CA2927720A1 (es) |
CL (1) | CL2016001100A1 (es) |
HK (1) | HK1221665A1 (es) |
MX (1) | MX2016006292A (es) |
PH (1) | PH12016500865A1 (es) |
RU (1) | RU2016117186A (es) |
TW (1) | TW201605441A (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170113459A (ko) * | 2016-03-31 | 2017-10-12 | 한미약품 주식회사 | 타다라필 및 암로디핀 함유 고형 복합제제 |
WO2017171508A1 (ko) * | 2016-03-31 | 2017-10-05 | 한미약품 주식회사 | 안정성 및 용출율이 개선된 타다라필 및 탐수로신 함유 캡슐 복합제제 |
US10350171B2 (en) * | 2017-07-06 | 2019-07-16 | Dexcel Ltd. | Celecoxib and amlodipine formulation and method of making the same |
JP7334144B2 (ja) * | 2018-03-16 | 2023-08-28 | 日本新薬株式会社 | 口腔内崩壊錠 |
CN109528675B (zh) * | 2018-12-31 | 2020-12-22 | 杭州康本医药科技有限公司 | 一种他达拉非肠溶片剂及其制备方法 |
KR102195162B1 (ko) | 2019-01-30 | 2020-12-24 | 단국대학교 천안캠퍼스 산학협력단 | 타다라필 함유 고체분산체 및 이의 제조방법 |
CN110638768B (zh) * | 2019-10-25 | 2024-04-16 | 株洲千金药业股份有限公司 | 一种治疗男性***功能障碍药物的制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO20002097L (no) | 1999-04-30 | 2001-10-26 | Lilly Icos Llc | Fremstillingsgjenstander |
AU2002350719A1 (en) * | 2002-11-29 | 2004-06-23 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
DE102005016981A1 (de) * | 2005-04-13 | 2006-10-19 | Bayer Healthcare Ag | Kombination zur Therapie bei benigner Prostatahyperplasie |
CN101678114A (zh) * | 2007-04-25 | 2010-03-24 | 特瓦制药工业有限公司 | 固体剂型 |
EP2167048B1 (en) * | 2007-05-30 | 2016-10-26 | Wockhardt Limited | A novel tablet dosage form |
US20100316711A1 (en) * | 2007-10-25 | 2010-12-16 | Bayer Yakuhin ,Ltd. | Nifedipine containing opress coated tablet and method of preparing same |
NZ594738A (en) * | 2009-01-23 | 2013-11-29 | Hanmi Science Co Ltd | Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same |
EP2322163A1 (en) * | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
EP2672959A1 (en) * | 2011-02-10 | 2013-12-18 | Synthon BV | Granulated composition comprising tadalafil and a disintegrant |
-
2014
- 2014-07-28 KR KR1020140096022A patent/KR20150056443A/ko not_active Application Discontinuation
- 2014-07-28 KR KR1020140096023A patent/KR101663238B1/ko active IP Right Grant
- 2014-11-03 KR KR1020140151219A patent/KR101665641B1/ko active IP Right Grant
- 2014-11-06 US US15/034,269 patent/US20160263040A1/en not_active Abandoned
- 2014-11-06 EP EP14861867.1A patent/EP3068380A4/en not_active Withdrawn
- 2014-11-06 JP JP2016528844A patent/JP2016539934A/ja active Pending
- 2014-11-06 CN CN201480062583.9A patent/CN105744930A/zh active Pending
- 2014-11-06 CA CA2927720A patent/CA2927720A1/en not_active Abandoned
- 2014-11-06 RU RU2016117186A patent/RU2016117186A/ru unknown
- 2014-11-06 MX MX2016006292A patent/MX2016006292A/es unknown
- 2014-11-06 AU AU2014349417A patent/AU2014349417A1/en not_active Abandoned
- 2014-11-11 TW TW103139057A patent/TW201605441A/zh unknown
- 2014-11-14 AR ARP140104278A patent/AR098415A1/es unknown
-
2016
- 2016-05-06 CL CL2016001100A patent/CL2016001100A1/es unknown
- 2016-05-10 PH PH12016500865A patent/PH12016500865A1/en unknown
- 2016-08-19 HK HK16109954.7A patent/HK1221665A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CL2016001100A1 (es) | 2016-11-11 |
TW201605441A (zh) | 2016-02-16 |
KR20150056444A (ko) | 2015-05-26 |
CN105744930A (zh) | 2016-07-06 |
KR20150056443A (ko) | 2015-05-26 |
AU2014349417A1 (en) | 2016-05-05 |
EP3068380A1 (en) | 2016-09-21 |
US20160263040A1 (en) | 2016-09-15 |
KR20150056461A (ko) | 2015-05-26 |
AR098415A1 (es) | 2016-05-26 |
PH12016500865A1 (en) | 2016-06-20 |
KR101663238B1 (ko) | 2016-10-14 |
KR101665641B1 (ko) | 2016-10-13 |
EP3068380A4 (en) | 2017-06-28 |
JP2016539934A (ja) | 2016-12-22 |
CA2927720A1 (en) | 2015-05-21 |
RU2016117186A (ru) | 2017-12-18 |
HK1221665A1 (zh) | 2017-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016500865A1 (en) | Composite formulation comprising tadalafil and amlodipine | |
IL239639A0 (en) | A modified spiropyrido {1,2-a} pyrazine derivative and its medicinal use as an HIV integrase inhibitor | |
MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
PH12015501993A1 (en) | Pyrazole-amide compound and medicinal uses therefor | |
SG10201804817TA (en) | Delayed release compositions of linaclotide | |
EP2657231A4 (en) | SUBSTITUTED AZOLES, ANTIVIRAL ACTIVE INGREDIENT, PHARMACEUTICAL COMPOSITION AND PROCESS FOR PREPARING AND USING SAME | |
PH12015500900B1 (en) | A stabilized pemetrexed formulation | |
PH12015502118A1 (en) | Pyridin-4-yl derivatives | |
MX2016003754A (es) | Una composicion farmaceutica estable que contiene amlodipina y valsartan. | |
PH12016500793A1 (en) | Turmeric extract containing soft pastilles | |
MX2021009377A (es) | Formulaciones de espuma y aparatos para su suministro. | |
PH12014502512A1 (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
MX339306B (es) | Agente anti-fungico. | |
MX357704B (es) | Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide. | |
EP2871187A4 (en) | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT | |
MX2016000775A (es) | Preparacion farmaceutica que comprende un derivado de aminopirazol. | |
WO2012169345A3 (en) | External skin preparation and production method of same | |
MX2016006480A (es) | Composicion antitranspirante. | |
IN2012CH05549A (es) | ||
EP2842938A4 (en) | NOVEL BETA-ALANINE DERIVATIVES, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | |
WO2016126115A3 (en) | Pharmaceutical composition comprising pitavastatin or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof | |
IN2013DE00880A (es) | ||
WO2014147568A8 (en) | Sterile s-adenosyl methionine with a high content of active isomer for injectable solutions, and procedure for obtaining it |